Can you pretreat malignant hyperthermia susceptible (MHS) patients with dantrolene?
Dantrolene pretreatment is not necessary, provided that a nontriggering anesthetic and appropriate monitoring are used and an adequate supply of dantrolene is available. Some experts have recommended dantrolene pretreatment of 2 mg/kg IV in a patient who has sustained a significant MH episode. Dantrolene may cause mild weakness in normal patients and significant weakness in patients with muscle disorders. Are MHS patients candidates for outpatient surgery? MHS patients can safely undergo outpatient surgery using nontriggering anesthetics. After an uneventful anesthetic, an observation period of 3 to 5 hours is recommended. Following discharge, they should be provided with an emergency telephone number to contact if problems arise. Should surgery be done without a biopsy? If there is a question of MH susceptibility and a biopsy has not been done, the patient should be considered susceptible and a nontriggering anesthetic technique used. What are the safe drugs? Safe: Local or regional a
Related Questions
- How exactly does dantrolene treat malignant hyperthermia when it is inhibiting Ca release just as succinylcholine (the culprit of malignant hyperthermia) is already inhibiting Ca?
- Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
- Is Malignant Hyperthermia (MH) associated with any other medical condition?
